AHAimee O. Hersh

Aimee O. Hersh

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aimee O. Hersh has a total of 218 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Tear‐Based Biomarker Trajectories Associated With Uveitis in Juvenile Idiopathic Arthritis: A Multicenter Prospective Study

    by Ilaria Macorra, Mariia Pavlenko, Mekibib Altaye, Hermine I. Brunner, John Bohnsack, Margaret H. Chang, Ashley M. Cooper, Stefanie Davidson, Alexandra Duell, Bharti Gangwani, et al.

    Objective: The extent of uveitis risk in juvenile idiopathic arthritis (JIA) is based on clinical factors. We aim to compare the trajectories of tear‐based biomarker levels of patients with JIA with and without uveitis. Methods: This prospective multicenter study included children with JIA at risk for uveitis (JIA‐no‐U) and those with JIA‐associated uveitis (JIA‐U). Serial tear samples were collected from each eye by Schirmer strips at enrollment and the first and second follow‐up visits (FU1 and FU2). S100 proteins, cytokines, and chemokines were assayed by Luminex or enzyme‐linked immunosorbent assay and compared between groups. Results: Fifty patients (37 JIA‐no‐U, 13 JIA‐U) contributed 222 samples (150 JIA‐no‐U, 73 JIA‐U). At enrollment, there were no significant differences in biomarker levels between JIA‐U and JIA‐no‐U. During follow‐up of patients with JIA‐U, monocyte chemoattractant protein 1 (MCP‐1) levels increased longitudinally from enrollment to FU1 and FU2 (LS mean ± SE 1.63 ± 0.31 to 2.46 ± 0.31, P = 0.005; and 2.89 ± 0.32, P < 0.0001), and there was a similar increase in CXCL10 (LS mean ± SE 4.39 ± 0.41 to 5.26 ± 0.41, P = 0.030; and 6.51 ± 0.43, P < 0.0001) and interleukin‐8 (IL‐8) levels from enrollment to FU1 and FU2 (LS mean ± SE 3.09 ± 0.30 to 4.25 ± 0.30, P = 0.006; and 4.65 ± 0.32, P ≤ 0.001). In both groups, S100A12 and S100A8/A9 levels increased from enrollment to follow‐up. Conclusion: Longitudinal changes in MCP‐1, CXCL10, and IL‐8 levels in tear fluid in JIA‐U may reflect inflammatory ocular processes and support the role of monocytes and interferon‐related pathways in uveitis. Lack of differences in S100 proteins may reflect systemic inflammation from arthritis. Tear‐based biomarkers may support clinical factors for identifying children with JIA who develop uveitis.

  • Age‐Specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta‐Analysis of Data From the Centers for Disease Control and Prevention Lupus Registries

    by Peter M. Izmirly, Elizabeth D. Ferucci, Aimee O. Hersh, Mary Beth Son, S. Sam Lim, Cristina Drenkard, Cynthia S. Crowson, Ali Duarte‐Garcia, Jill P. Buyon, Heather T. Gold, et al.

    Objective: Epidemiologic estimates for age at systemic lupus erythematosus (SLE) diagnosis are limited, particularly for men and racial and ethnic subpopulations in the United States. Leveraging the Centers for Disease Control and Prevention (CDC) National Lupus Registry network of population‐based SLE registries, meta‐analyses were performed estimating age‐specific incidence of SLE by sex, race, and ethnicity. Methods: The CDC network of SLE registries includes five state‐based registries, plus a sixth Indian Health Service registry. Incidence periods spanned calendar years 2002 to 2018. Registries provided age‐specific incidence of SLE, fulfilling the American College of Rheumatology SLE classification criteria, per 100,000 person‐years, stratified by sex, race, and ethnicity for the meta‐analyses. Results: Incidence rates among women were highest for those aged 30 to 39 years (12.7, 95% confidence interval [CI] 9.5–16.8), whereas rates among men were highest for those aged 60 to 69 years (2.1, 95% CI 1.3–3.4). Black women aged 20 to 39 years had the highest SLE incidence rates (23.6, 95% CI 20.7–26.8). Among women diagnosed with SLE before age 20 years, incidence was highest among Asian individuals (6.5, 95% CI 2.8–15.2). Among women diagnosed with SLE after age 60 years, incidence was highest among American Indian/Alaska Native individuals (9.4, 95% CI 3.4–15.4). Weighted percentages show 10.0% of those with SLE were diagnosed before age 20 years, whereas 15.1% were diagnosed after age 60 years. The largest proportion of individuals with SLE (22.1%) was diagnosed between ages 30 and 39 years. Conclusion: This study provides comprehensive sex‐ and race‐specific estimates of age at SLE diagnosis. The substantial later‐in‐life SLE incidence among men and disease burden in pediatric and older populations should raise awareness in considering SLE in the differential diagnosis in previously underrecognized groups. image

  • Top Cited Papers

    2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus

    by Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'ERa, Alí Duarte‐García, Linda T. Hiraki, Mary Beth F. Son, Victoria P. Werth, Cynthia Aranow, April Barnado, et al.

    Objective: To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods: Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results: We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion: This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.


  • Top Cited Papers

    2025 American College of Rheumatology ( ACR ) Guideline for the Treatment of Systemic Lupus Erythematosus

    by Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'ERa, Alí Duarte‐García, Linda T. Hiraki, Mary Beth F. Son, Victoria P. Werth, Cynthia Aranow, April Barnado, et al.

    Objective: To provide evidence‐based and expert guidance for the treatment and management of non‐renal systemic lupus erythematosus (SLE); treatment and management of lupus nephritis are addressed in a separate guideline. Methods: Clinical questions for treatment and management of SLE were developed in the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were developed for each PICO question, and the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) methodology was used to assess evidence quality and formulate recommendations. The Voting Panel achieved a consensus of ≥70% agreement on the direction (for or against) and strength (strong or conditional) of each recommendation. Results: We present recommendations and ungraded, consensus‐based good practice statements for the treatment and management of SLE that are applicable to pediatric and adult patients. Recommendations emphasize uniform treatment with hydroxychloroquine, limiting duration of glucocorticoid use, and early introduction of conventional and/or biologic immunosuppressive therapies to achieve and maintain control of SLE inflammation (remission or a low level of disease activity), reduce SLE‐related morbidity and mortality, and minimize medication‐related toxicities. Conclusion: This guideline presents direction regarding treatment and management of SLE and provides a foundation for well‐informed, shared clinician–patient decision‐making. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each person with SLE.


  • Top Cited Papers

    2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

    by Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'ERa, Alí Duarte‐García, Linda T. Hiraki, Brad H. Rovin, Mary Beth F. Son, Anthony Alvarado, Cynthia Aranow, et al.

    Objective: The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.Methods: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.Results: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.Conclusion: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.


  • Top Cited Papers

    2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis

    by Lisa R. Sammaritano, Anca Askanase, Bonnie L. Bermas, Maria Dall'ERa, Alí Duarte‐García, Linda T. Hiraki, Brad H. Rovin, Mary Beth F. Son, Anthony Alvarado, Cynthia Aranow, et al.

    Objective: The objective is to provide evidence‐based and expert guidance for the screening, treatment, and management of lupus nephritis.Methods: The Core Team developed clinical questions for screening, treatment, and management of lupus nephritis using the PICO format (population, intervention, comparator, and outcome). Systematic literature reviews were completed for each PICO question, and the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology was used to assess the quality of evidence and to formulate recommendations. The Voting Panel achieved a consensus ≥70% on the direction (for or against) and strength (strong or conditional) of each recommendation.Results: We present 28 graded recommendations (7 strong, 21 conditional) and 13 ungraded, consensus‐based good practice statements for the screening and management of lupus nephritis. Our recommendations focus on the unifying principle that lupus nephritis therapy is continuous and ongoing, rather than consisting of discrete induction/initial and maintenance/subsequent therapies. Therapy should include pulse glucocorticoids followed by oral glucocorticoid taper and two additional immunosuppressive agents for 3–5 years for those achieving complete renal response.Conclusion: This guideline provides direction for clinicians regarding screening and treatment decisions for management of lupus nephritis. These recommendations should not be used to limit or deny access to therapies, as treatment decisions may vary due to the unique clinical situation and personal preferences of each individual patient.


  • Open Access

    Patient and parent perspectives on an academic rheumatology transition clinic

    by Rebecca S. Overbury, Devin Eddington, Katherine Sward, Aimee Hersh


  • Open Access

    Racial Disparities and Achievement of the Low Lupus Disease Activity State: A CARRA Registry Study

    by William Daniel Soulsby, Rebecca Olveda, Jie He, Laura Berbert, Edie Weller, Kamil E. Barbour, Kurt J. Greenlund, Laura E. Schanberg, Emily von Scheven, Aimee Hersh, et al.

    Objective: Differential disease control may contribute to racial disparities in outcomes of childhood‐onset systemic lupus erythematosus (cSLE). We evaluated associations of race and individual‐ or neighborhood‐level social determinants of health (SDoH) with achievement of low lupus disease activity state (LLDAS), a clinically relevant treatment target.Methods: In this cSLE cohort study using the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry, the primary exposure was self‐reported race and ethnicity, and collected SDoH included insurance status and area deprivation index (ADI). Outcomes included LLDAS, disease activity, and time‐averaged prednisone exposure. Associations among race and ethnicity, SDoH, and disease activity were estimated with multivariable regression models, adjusting for disease‐related and demographic factors.Results: Among 540 children with cSLE, 27% identified as Black, 25% identified as White, 23% identified as Latino/a, 11% identified as Asian, 9% identified as more than one race, and 5% identified as other. More Black children (41%) lived in neighborhoods of highest ADI compared to White children (16%). Black race was associated with lower LLDAS achievement (adjusted odds ratio 0.56, 95% confidence interval [CI] 0.38–0.82) and higher disease activity (adjusted β 0.94, 95% CI 0.11–1.78). The highest ADI was not associated with lower LLDAS achievement on adjustment for renal disease and insurance. However, renal disease was found to be a significant mediator (P = 0.04) of the association between ADI and prednisone exposure.Conclusions: Children with cSLE who identified as Black are less likely to achieve LLDAS and have a higher disease activity. Living in areas of higher ADI may relate to renal disease and subsequent prednisone exposure. Strategies to address root causes will be important to design interventions mitigating cSLE racial disparities.


  • Disease Course, Treatments, and Outcomes of Children With Systemic Juvenile Idiopathic Arthritis–Associated Lung Disease

    by Yannan Huang, Laura Sompii‐Montgomery, Jessica Patti, Alex Pickering, Shima Yasin, Thuy Do, Elizabeth Baker, Denny Gao, Rabheh Abdul‐Aziz, Edward M. Behrens, et al.

    Objective: Systemic juvenile idiopathic arthritis–associated lung disease (SJIA‐LD) is a life‐threatening disease complication. Key questions remain regarding clinical course and optimal treatment approaches. The objectives of the study were to detail management strategies after SJIA‐LD detection, characterize overall disease courses, and measure long‐term outcomes.Methods: This was a prospective cohort study. Clinical data were abstracted from the electronic medical record, including current clinical status and changes since diagnosis. Serum biomarkers were determined and correlated with presence of LD.Results: We enrolled 41 patients with SJIA‐LD, 85% with at least one episode of macrophage activation syndrome and 41% with adverse reactions to a biologic. Although 93% of patients were alive at last follow‐up (median 2.9 years), 37% progressed to requiring chronic oxygen or other ventilator support, and 65% of patients had abnormal overnight oximetry studies, which changed over time. Eighty‐four percent of patients carried the HLA‐DRB1*15 haplotype, significantly more than patients without LD. Patients with SJIA‐LD also showed markedly elevated serum interleukin‐18 (IL‐18), variable C‐X‐C motif chemokine ligand 9 (CXCL9), and significantly elevated matrix metalloproteinase 7. Treatment strategies showed variable use of anti–IL‐1/6 biologics and addition of other immunomodulatory treatments and lung‐directed therapies. We found a broad range of current clinical status independent of time from diagnosis or continued biologic treatment. Multidomain measures of change showed imaging features were the least likely to improve with time.Conclusion: Patients with SJIA‐LD had highly varied courses, with lower mortality than previously reported but frequent hypoxia and requirement for respiratory support. Treatment strategies were highly varied, highlighting an urgent need for focused clinical trials.


  • Childhood‐Onset Lupus Nephritis in the Childhood Arthritis and Rheumatology Research Alliance Registry: Short‐Term Kidney Status and Variation in Care

    by Emily A. Smitherman, Rouba A. Chahine, Timothy Beukelman, Laura B. Lewandowski, A. K. M. Fazlur Rahman, Scott E. Wenderfer, Jeffrey R. Curtis, Aimee O. Hersh, for the CARRA Registry Investigators

    Objective: The goal was to characterize short‐term kidney status and describe variation in early care utilization in a multicenter cohort of patients with childhood‐onset systemic lupus erythematosus (cSLE) and nephritis.Methods: We analyzed previously collected prospective data from North American patients with cSLE with kidney biopsy‐proven nephritis enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from March 2017 through December 2019. We determined the proportion of patients with abnormal kidney status at the most recent registry visit and applied generalized linear mixed models to identify associated factors. We also calculated frequency of medication use, both during induction and ever recorded.Results: We identified 222 patients with kidney biopsy–proven nephritis, with 64% class III/IV nephritis on initial biopsy. At the most recent registry visit at median (interquartile range) of 17 (8–29) months from initial kidney biopsy, 58 of 106 patients (55%) with available data had abnormal kidney status. This finding was associated with male sex (odds ratio [OR] 3.88, 95% confidence interval [95% CI] 1.21–12.46) and age at cSLE diagnosis (OR 1.23, 95% CI 1.01–1.49). Patients with class IV nephritis were more likely than class III to receive cyclophosphamide and rituximab during induction. There was substantial variation in mycophenolate, cyclophosphamide, and rituximab ever use patterns across rheumatology centers.Conclusion: In this cohort with predominately class III/IV nephritis, male sex and older age at cSLE diagnosis were associated with abnormal short‐term kidney status. We also observed substantial variation in contemporary medication use for pediatric lupus nephritis between pediatric rheumatology centers. Additional studies are needed to better understand the impact of this variation on long‐term kidney outcomes.